Superkines, des cytokines aux fonctions mieux ciblées

Rémi J. Creusot; Ignacio Moraga

doi:10.1051/medsci/2013294004

Accueil

Tous les numéros

Volume 29 / Numéro 4 (Avril 2013)

Med Sci (Paris), 29 4 (2013) 345-349

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 29, Numéro 4, Avril 2013


Page(s)		345 - 349
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/2013294004
Publié en ligne		26 avril 2013

Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009 ; 9 : 480–490. [CrossRef] [PubMed] [Google Scholar]
Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol 2009 ; 27 : 29–60. [CrossRef] [PubMed] [Google Scholar]
Garbers C, Hermanns HM, Schaper F, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 2012 ; 23 : 85–97. [CrossRef] [PubMed] [Google Scholar]
Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003 ; 112 : 653–665. [CrossRef] [PubMed] [Google Scholar]
Levin AM, Bates DL, Ring AM, et al. Exploiting a natural conformational switch to engineer an interleukin-2 superkine. Nature 2012 ; 484 : 529–533. [CrossRef] [PubMed] [Google Scholar]
Ring AM, Lin JX, Feng D, et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 2012 ; 13 : 1187–1195. [CrossRef] [PubMed] [Google Scholar]
Junttila IS, Creusot RJ, Moraga I, et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat Chem Biol 2012 ; 8 : 990–998. [CrossRef] [PubMed] [Google Scholar]
Martin R. Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases? Trends Pharmacol Sci 2003 ; 24 : 613–616. [CrossRef] [PubMed] [Google Scholar]
Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012 ; 11 : 763–776. [CrossRef] [PubMed] [Google Scholar]
Thomas C, Moraga I, Levin D, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011 ; 146 : 621–632. [CrossRef] [PubMed] [Google Scholar]
Collison LW, Delgoffe GM, Guy CS, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012 ; 13 : 290–299. [CrossRef] [PubMed] [Google Scholar]
Terrier B, Mouthon L. Lupus érythémateux systémique. Traitements par anticorps monoclonaux et molécules recombinantes. Med Sci (Paris) 2013 ; 29 : 65–73. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009 ; 9 : 480–490. [CrossRef] [PubMed] [Google Scholar]

[2] Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol 2009 ; 27 : 29–60. [CrossRef] [PubMed] [Google Scholar]

[3] Garbers C, Hermanns HM, Schaper F, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 2012 ; 23 : 85–97. [CrossRef] [PubMed] [Google Scholar]

[4] Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003 ; 112 : 653–665. [CrossRef] [PubMed] [Google Scholar]

[5] Levin AM, Bates DL, Ring AM, et al. Exploiting a natural conformational switch to engineer an interleukin-2 superkine. Nature 2012 ; 484 : 529–533. [CrossRef] [PubMed] [Google Scholar]

[6] Ring AM, Lin JX, Feng D, et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 2012 ; 13 : 1187–1195. [CrossRef] [PubMed] [Google Scholar]

[7] Junttila IS, Creusot RJ, Moraga I, et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat Chem Biol 2012 ; 8 : 990–998. [CrossRef] [PubMed] [Google Scholar]

[8] Martin R. Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases? Trends Pharmacol Sci 2003 ; 24 : 613–616. [CrossRef] [PubMed] [Google Scholar]

[9] Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012 ; 11 : 763–776. [CrossRef] [PubMed] [Google Scholar]

[10] Thomas C, Moraga I, Levin D, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011 ; 146 : 621–632. [CrossRef] [PubMed] [Google Scholar]

[11] Collison LW, Delgoffe GM, Guy CS, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012 ; 13 : 290–299. [CrossRef] [PubMed] [Google Scholar]

[12] Terrier B, Mouthon L. Lupus érythémateux systémique. Traitements par anticorps monoclonaux et molécules recombinantes. Med Sci (Paris) 2013 ; 29 : 65–73. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]